Form 4: Oramed Director Shapiro Boosts Future Equity Holdings

Oramed Pharmaceuticals Director Benjamin Shapiro reported the acquisition of 33,500 Restricted Stock Units, set to vest over future periods.

Summary

• Benjamin Shapiro, a Director at Oramed Pharmaceuticals Inc. (ORMP), reported changes in his beneficial ownership.
• On December 31, 2025, Shapiro acquired 30,000 Restricted Stock Units (RSUs). These RSUs will vest ratably in three annual tranches, commencing January 1, 2027.
• Also on December 31, 2025, Shapiro acquired an additional 3,500 RSUs. These RSUs will vest in quarterly installments over a one-year period, beginning April 1, 2026.
• Each RSU represents the right to receive one share of Oramed's common stock, par value $0.012 per share.
• Following these reported transactions, Shapiro's direct beneficial ownership stands at 123,220 shares.
• Additionally, Shapiro indirectly beneficially owns 1,900,000 shares through a trust where he serves as a trustee and beneficiary.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is generally a positive signal, indicating continued alignment of management interests with shareholder value and a commitment to the company's future. It's a standard compensation practice.

Positives

• Director Benjamin Shapiro was granted 33,500 Restricted Stock Units (RSUs), aligning his interests with long-term shareholder value.
• The vesting schedules for the RSUs (starting April 1, 2026, and January 1, 2027) indicate a commitment to future performance and retention of key management.

Future Outlook

The grants of Restricted Stock Units (RSUs) to Director Benjamin Shapiro indicate a future-oriented compensation structure, with vesting schedules extending into 2026 and 2027. This aligns management incentives with the company's long-term performance.

Industry Context

This Form 4 filing reflects a standard practice in the pharmaceutical and biotechnology industry where executive and director compensation often includes equity grants like Restricted Stock Units (RSUs) to incentivize long-term commitment and align interests with shareholders. Such grants are common for retaining key personnel in R&D-intensive sectors.

Related Party Transactions

• Benjamin Shapiro indirectly beneficially owns 1,900,000 shares through a trust where he is a trustee and beneficiary.

Stakeholder Impact

• Shareholders: The RSU grants align the director's long-term interests with shareholder value, potentially fostering more stable and growth-oriented decision-making.
• Employees: May signal stability in leadership and a commitment to long-term strategic goals.

Next Steps

• The 3,500 RSUs will begin vesting in quarterly installments starting April 1, 2026.
• The 30,000 RSUs will begin vesting ratably in three annual tranches starting January 1, 2027.

Key Dates

Recommendation

The filing details a routine grant of Restricted Stock Units to a director, which is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. While positive for governance and retention, it does not present new information that would fundamentally alter the investment thesis for Oramed Pharmaceuticals, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Oramed Pharmaceuticals, ORMP, Benjamin Shapiro, Form 4, Insider Trading, Restricted Stock Units, RSUs, Beneficial Ownership, Director Compensation, Equity Grant